NCT02815280View on ClinicalTrials.gov

A Study to Compare the Efficacy and Safety of Topical Administration of FMX-101 for Treatment of Moderate-to-Severe Acne

PHASE3CompletedINTERVENTIONAL
Enrollment

495

Participants

Timeline

Start Date

May 31, 2016

Primary Completion Date

October 13, 2017

Study Completion Date

October 13, 2017

Conditions
Acne Vulgaris
Interventions
DRUG

FMX-101, 4% minocycline foam

FMX-101, 4% minocycline foam applied topically once daily for 12 weeks

DRUG

Vehicle Foam

Vehicle foam applied topically once daily for 12 weeks

Trial Locations (36)

10022

New York

10458

The Bronx

18201

Hazleton

27612

Raleigh

30060

Marietta

30078

Snellville

33016

Hialeah

33126

Miami

33172

Sweetwater

33175

Miami

37072

Goodlettsville

37421

Chattanooga

42303

Owensboro

44121

Cleveland

46032

Carmel

46256

Indianapolis

48202

Detroit

48346

Clarkston

60611

Chicago

66215

Overland Park

70526

Crowley

72758

Rogers

77479

Sugar Land

77640

Port Arthur

78130

New Braunfels

78229

San Antonio

78746

Austin

80220

Denver

84117

Salt Lake City

85308

Glendale

87106

Albuquerque

92049

Oceanside

98104

Seattle

07042

Montclair

07044

Verona

Unknown

Santo Domingo

All Listed Sponsors
lead

Vyne Therapeutics Inc.

INDUSTRY

NCT02815280 - A Study to Compare the Efficacy and Safety of Topical Administration of FMX-101 for Treatment of Moderate-to-Severe Acne | Biotech Hunter | Biotech Hunter